Table 1 Patient characteristics and response to R-DHAP
Overall cohort | 1 cycle | 2 cycles | 3 cycles | 4 cycles | P-values | |
|---|---|---|---|---|---|---|
R-DHAP | R-DHAP | R-DHAP | R-DHAP | |||
Patients, n (%) | 122 (100) | 31 (25) | 61 (50) | 14 (12) | 16 (13) | / |
Gender, n (%) | 0.17 | |||||
Male | 82 (67) | 20 (65) | 37 (61) | 11 (79) | 14 (88) | |
Female | 40 (33) | 11 (35) | 24 (39) | 3 (21) | 2 (12) | |
First diagnosis and previous Tx | ||||||
Mean age at first diagnosis (SD) | 53 (12) | 53 (13) | 54 (11) | 51 (13) | 54 (12) | 0.73 |
Stage at first diagnosis, n (%) | 0.01 | |||||
I | 7 (6) | 1 (3) | 2 (3) | 4 (29) | 0 (0) | |
II | 26 (21) | 4 (13) | 14 (23) | 3 (21) | 5 (31) | |
III | 39 (32) | 12 (39) | 19 (31) | 3 (21) | 5 (31) | |
IV | 48 (39) | 13 (42) | 26 (43) | 3 (21) | 6 (38) | |
Not known | 2 (2) | 1 (3) | 0 (0) | 1 (7) | 0 (0) | |
CHOP-like therapy, n (%) | 113 (93) | 29 (94) | 58 (95) | 12 (86) | 14 (88) | 0.35 |
Other, n (%) | 8 (6) | 2 (6) | 2 (3) | 2 (14) | 2 (12) | |
Not known, n (%) | 1 (1) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | |
Rituximab-containing, n (%) | 96 (79) | 30 (97) | 47 (77) | 10 (71) | 9 (56) | 0.01 |
Relapse | ||||||
TTR after last treatment, n (%) | 0.01 | |||||
Refractory or <12 months | 79 (65) | 26 (84) | 40 (66) | 6 (43) | 7 (44) | |
≥12 months | 43 (35) | 5 (16) | 21 (34) | 8 (57) | 9 (56) | |
Mean age at 1. R-DHAP (SD) | 57 (12) | 56 (15) | 57 (11) | 56 (13) | 57 (13) | 0.98 |
Months between last treatment and 1. R-DHAP, mean (SD) | 19 (29) | 8 (15) | 17 (28) | 43 (47) | 27 (23) | <0.01 |
Response to R-DHAP, n (%) | <0.01 | |||||
CR | 19 (16) | 0 (0) | 11 (18) | 5 (36) | 3 (19) | |
CRu | 6 (5) | 0 (0) | 5 (8) | 0 (0) | 1 (6) | |
PR | 39 (32) | 3 (10) | 18 (30) | 6 (43) | 12 (75) | |
StD | 18 (15) | 5 (16) | 11 (18) | 2 (14) | 0 (0) | |
PD | 35 (29) | 18 (58) | 16 (26) | 1 (7) | 0 (0) | |
Not known | 5 (4) | 5 (16) | 0 (0) | 0 (0) | 0 (0) |